ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global New Molecular Entity (NME) Drug Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-29A16091
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global New Molecular Entity NME Drug Market Research Report 2023
BUY CHAPTERS

Global New Molecular Entity (NME) Drug Market Research Report 2025

Code: QYRE-Auto-29A16091
Report
June 2025
Pages:105
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
UCB
Otsuka Pharmaceutical
Eli Lilly
Genentech Inc
Eisai Co Ltd
Biogen
Menarini Group
GSK
CHEST
Pfizer Inc
ACADIA Pharmaceuticals
Incyte
Pharming
LEO Pharma
Novartis
Argenx
Takeda
AbbVie
Sanofi
Travere
Reata
Cidara
Melinta
Bayer Hlthcare
Immumnocore

New Molecular Entity (NME) Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

New Molecular Entity (NME) Drug Market

New Molecular Entity (NME) Drug Market

The global market for New Molecular Entity (NME) Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
New Molecular Entity refers to a chemical structure with certain biological activity. Due to its weak activity, low selectivity, poor absorption, or high toxicity, it cannot be directly used as medicine. However, as a new structural type and clue substance, through structural transformation and modification, drugs with excellent pharmacological effects can be obtained.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for New Molecular Entity (NME) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding New Molecular Entity (NME) Drug.
The New Molecular Entity (NME) Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global New Molecular Entity (NME) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the New Molecular Entity (NME) Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of New Molecular Entity (NME) Drug Market Report

Report Metric Details
Report Name New Molecular Entity (NME) Drug Market
CAGR 5%
Segment by Type
  • Antibody
  • Polypeptide
  • Small Molecule Drug
  • Other
Segment by Application
  • Hospital
  • Clinic
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company UCB, Otsuka Pharmaceutical, Eli Lilly, Genentech, Eisai, Biogen, Menarini Group, GSK, Chest, Travere, Reata, Pfizer, Acadia Pharmaceuticals, Incyte, Cidara, Melinta, Pharming, LEO Pharma, Novartis, Argenx, Takeda, AbbVie, Bayer Hlthcare, Sanofi, Immumnocore
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of New Molecular Entity (NME) Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the New Molecular Entity (NME) Drug Market report?

Ans: The main players in the New Molecular Entity (NME) Drug Market are UCB, Otsuka Pharmaceutical, Eli Lilly, Genentech, Eisai, Biogen, Menarini Group, GSK, Chest, Travere, Reata, Pfizer, Acadia Pharmaceuticals, Incyte, Cidara, Melinta, Pharming, LEO Pharma, Novartis, Argenx, Takeda, AbbVie, Bayer Hlthcare, Sanofi, Immumnocore

What are the Application segmentation covered in the New Molecular Entity (NME) Drug Market report?

Ans: The Applications covered in the New Molecular Entity (NME) Drug Market report are Hospital, Clinic

What are the Type segmentation covered in the New Molecular Entity (NME) Drug Market report?

Ans: The Types covered in the New Molecular Entity (NME) Drug Market report are Antibody, Polypeptide, Small Molecule Drug, Other

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global New Molecular Entity (NME) Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antibody
1.2.3 Polypeptide
1.2.4 Small Molecule Drug
1.2.5 Other
1.3 Market by Application
1.3.1 Global New Molecular Entity (NME) Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global New Molecular Entity (NME) Drug Market Perspective (2020-2031)
2.2 Global New Molecular Entity (NME) Drug Growth Trends by Region
2.2.1 Global New Molecular Entity (NME) Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 New Molecular Entity (NME) Drug Historic Market Size by Region (2020-2025)
2.2.3 New Molecular Entity (NME) Drug Forecasted Market Size by Region (2026-2031)
2.3 New Molecular Entity (NME) Drug Market Dynamics
2.3.1 New Molecular Entity (NME) Drug Industry Trends
2.3.2 New Molecular Entity (NME) Drug Market Drivers
2.3.3 New Molecular Entity (NME) Drug Market Challenges
2.3.4 New Molecular Entity (NME) Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top New Molecular Entity (NME) Drug Players by Revenue
3.1.1 Global Top New Molecular Entity (NME) Drug Players by Revenue (2020-2025)
3.1.2 Global New Molecular Entity (NME) Drug Revenue Market Share by Players (2020-2025)
3.2 Global New Molecular Entity (NME) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by New Molecular Entity (NME) Drug Revenue
3.4 Global New Molecular Entity (NME) Drug Market Concentration Ratio
3.4.1 Global New Molecular Entity (NME) Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by New Molecular Entity (NME) Drug Revenue in 2024
3.5 Global Key Players of New Molecular Entity (NME) Drug Head office and Area Served
3.6 Global Key Players of New Molecular Entity (NME) Drug, Product and Application
3.7 Global Key Players of New Molecular Entity (NME) Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 New Molecular Entity (NME) Drug Breakdown Data by Type
4.1 Global New Molecular Entity (NME) Drug Historic Market Size by Type (2020-2025)
4.2 Global New Molecular Entity (NME) Drug Forecasted Market Size by Type (2026-2031)
5 New Molecular Entity (NME) Drug Breakdown Data by Application
5.1 Global New Molecular Entity (NME) Drug Historic Market Size by Application (2020-2025)
5.2 Global New Molecular Entity (NME) Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America New Molecular Entity (NME) Drug Market Size (2020-2031)
6.2 North America New Molecular Entity (NME) Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America New Molecular Entity (NME) Drug Market Size by Country (2020-2025)
6.4 North America New Molecular Entity (NME) Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe New Molecular Entity (NME) Drug Market Size (2020-2031)
7.2 Europe New Molecular Entity (NME) Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe New Molecular Entity (NME) Drug Market Size by Country (2020-2025)
7.4 Europe New Molecular Entity (NME) Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific New Molecular Entity (NME) Drug Market Size (2020-2031)
8.2 Asia-Pacific New Molecular Entity (NME) Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific New Molecular Entity (NME) Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific New Molecular Entity (NME) Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America New Molecular Entity (NME) Drug Market Size (2020-2031)
9.2 Latin America New Molecular Entity (NME) Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America New Molecular Entity (NME) Drug Market Size by Country (2020-2025)
9.4 Latin America New Molecular Entity (NME) Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa New Molecular Entity (NME) Drug Market Size (2020-2031)
10.2 Middle East & Africa New Molecular Entity (NME) Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa New Molecular Entity (NME) Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa New Molecular Entity (NME) Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 UCB
11.1.1 UCB Company Details
11.1.2 UCB Business Overview
11.1.3 UCB New Molecular Entity (NME) Drug Introduction
11.1.4 UCB Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.1.5 UCB Recent Development
11.2 Otsuka Pharmaceutical
11.2.1 Otsuka Pharmaceutical Company Details
11.2.2 Otsuka Pharmaceutical Business Overview
11.2.3 Otsuka Pharmaceutical New Molecular Entity (NME) Drug Introduction
11.2.4 Otsuka Pharmaceutical Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.2.5 Otsuka Pharmaceutical Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly New Molecular Entity (NME) Drug Introduction
11.3.4 Eli Lilly Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.3.5 Eli Lilly Recent Development
11.4 Genentech
11.4.1 Genentech Company Details
11.4.2 Genentech Business Overview
11.4.3 Genentech New Molecular Entity (NME) Drug Introduction
11.4.4 Genentech Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.4.5 Genentech Recent Development
11.5 Eisai
11.5.1 Eisai Company Details
11.5.2 Eisai Business Overview
11.5.3 Eisai New Molecular Entity (NME) Drug Introduction
11.5.4 Eisai Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.5.5 Eisai Recent Development
11.6 Biogen
11.6.1 Biogen Company Details
11.6.2 Biogen Business Overview
11.6.3 Biogen New Molecular Entity (NME) Drug Introduction
11.6.4 Biogen Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.6.5 Biogen Recent Development
11.7 Menarini Group
11.7.1 Menarini Group Company Details
11.7.2 Menarini Group Business Overview
11.7.3 Menarini Group New Molecular Entity (NME) Drug Introduction
11.7.4 Menarini Group Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.7.5 Menarini Group Recent Development
11.8 GSK
11.8.1 GSK Company Details
11.8.2 GSK Business Overview
11.8.3 GSK New Molecular Entity (NME) Drug Introduction
11.8.4 GSK Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.8.5 GSK Recent Development
11.9 Chest
11.9.1 Chest Company Details
11.9.2 Chest Business Overview
11.9.3 Chest New Molecular Entity (NME) Drug Introduction
11.9.4 Chest Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.9.5 Chest Recent Development
11.10 Travere
11.10.1 Travere Company Details
11.10.2 Travere Business Overview
11.10.3 Travere New Molecular Entity (NME) Drug Introduction
11.10.4 Travere Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.10.5 Travere Recent Development
11.11 Reata
11.11.1 Reata Company Details
11.11.2 Reata Business Overview
11.11.3 Reata New Molecular Entity (NME) Drug Introduction
11.11.4 Reata Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.11.5 Reata Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Details
11.12.2 Pfizer Business Overview
11.12.3 Pfizer New Molecular Entity (NME) Drug Introduction
11.12.4 Pfizer Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.12.5 Pfizer Recent Development
11.13 Acadia Pharmaceuticals
11.13.1 Acadia Pharmaceuticals Company Details
11.13.2 Acadia Pharmaceuticals Business Overview
11.13.3 Acadia Pharmaceuticals New Molecular Entity (NME) Drug Introduction
11.13.4 Acadia Pharmaceuticals Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.13.5 Acadia Pharmaceuticals Recent Development
11.14 Incyte
11.14.1 Incyte Company Details
11.14.2 Incyte Business Overview
11.14.3 Incyte New Molecular Entity (NME) Drug Introduction
11.14.4 Incyte Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.14.5 Incyte Recent Development
11.15 Cidara
11.15.1 Cidara Company Details
11.15.2 Cidara Business Overview
11.15.3 Cidara New Molecular Entity (NME) Drug Introduction
11.15.4 Cidara Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.15.5 Cidara Recent Development
11.16 Melinta
11.16.1 Melinta Company Details
11.16.2 Melinta Business Overview
11.16.3 Melinta New Molecular Entity (NME) Drug Introduction
11.16.4 Melinta Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.16.5 Melinta Recent Development
11.17 Pharming
11.17.1 Pharming Company Details
11.17.2 Pharming Business Overview
11.17.3 Pharming New Molecular Entity (NME) Drug Introduction
11.17.4 Pharming Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.17.5 Pharming Recent Development
11.18 LEO Pharma
11.18.1 LEO Pharma Company Details
11.18.2 LEO Pharma Business Overview
11.18.3 LEO Pharma New Molecular Entity (NME) Drug Introduction
11.18.4 LEO Pharma Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.18.5 LEO Pharma Recent Development
11.19 Novartis
11.19.1 Novartis Company Details
11.19.2 Novartis Business Overview
11.19.3 Novartis New Molecular Entity (NME) Drug Introduction
11.19.4 Novartis Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.19.5 Novartis Recent Development
11.20 Argenx
11.20.1 Argenx Company Details
11.20.2 Argenx Business Overview
11.20.3 Argenx New Molecular Entity (NME) Drug Introduction
11.20.4 Argenx Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.20.5 Argenx Recent Development
11.21 Takeda
11.21.1 Takeda Company Details
11.21.2 Takeda Business Overview
11.21.3 Takeda New Molecular Entity (NME) Drug Introduction
11.21.4 Takeda Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.21.5 Takeda Recent Development
11.22 AbbVie
11.22.1 AbbVie Company Details
11.22.2 AbbVie Business Overview
11.22.3 AbbVie New Molecular Entity (NME) Drug Introduction
11.22.4 AbbVie Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.22.5 AbbVie Recent Development
11.23 Bayer Hlthcare
11.23.1 Bayer Hlthcare Company Details
11.23.2 Bayer Hlthcare Business Overview
11.23.3 Bayer Hlthcare New Molecular Entity (NME) Drug Introduction
11.23.4 Bayer Hlthcare Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.23.5 Bayer Hlthcare Recent Development
11.24 Sanofi
11.24.1 Sanofi Company Details
11.24.2 Sanofi Business Overview
11.24.3 Sanofi New Molecular Entity (NME) Drug Introduction
11.24.4 Sanofi Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.24.5 Sanofi Recent Development
11.25 Immumnocore
11.25.1 Immumnocore Company Details
11.25.2 Immumnocore Business Overview
11.25.3 Immumnocore New Molecular Entity (NME) Drug Introduction
11.25.4 Immumnocore Revenue in New Molecular Entity (NME) Drug Business (2020-2025)
11.25.5 Immumnocore Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
UCB
Otsuka Pharmaceutical
Eli Lilly
Genentech Inc
Eisai Co Ltd
Biogen
Menarini Group
GSK
CHEST
Pfizer Inc
ACADIA Pharmaceuticals
Incyte
Pharming
LEO Pharma
Novartis
Argenx
Takeda
AbbVie
Sanofi
Travere
Reata
Cidara
Melinta
Bayer Hlthcare
Immumnocore
List of Tables
 Table 1. Global New Molecular Entity (NME) Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Antibody
 Table 3. Key Players of Polypeptide
 Table 4. Key Players of Small Molecule Drug
 Table 5. Key Players of Other
 Table 6. Global New Molecular Entity (NME) Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global New Molecular Entity (NME) Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global New Molecular Entity (NME) Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global New Molecular Entity (NME) Drug Market Share by Region (2020-2025)
 Table 10. Global New Molecular Entity (NME) Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global New Molecular Entity (NME) Drug Market Share by Region (2026-2031)
 Table 12. New Molecular Entity (NME) Drug Market Trends
 Table 13. New Molecular Entity (NME) Drug Market Drivers
 Table 14. New Molecular Entity (NME) Drug Market Challenges
 Table 15. New Molecular Entity (NME) Drug Market Restraints
 Table 16. Global New Molecular Entity (NME) Drug Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global New Molecular Entity (NME) Drug Market Share by Players (2020-2025)
 Table 18. Global Top New Molecular Entity (NME) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in New Molecular Entity (NME) Drug as of 2024)
 Table 19. Ranking of Global Top New Molecular Entity (NME) Drug Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by New Molecular Entity (NME) Drug Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of New Molecular Entity (NME) Drug, Headquarters and Area Served
 Table 22. Global Key Players of New Molecular Entity (NME) Drug, Product and Application
 Table 23. Global Key Players of New Molecular Entity (NME) Drug, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global New Molecular Entity (NME) Drug Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global New Molecular Entity (NME) Drug Revenue Market Share by Type (2020-2025)
 Table 27. Global New Molecular Entity (NME) Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global New Molecular Entity (NME) Drug Revenue Market Share by Type (2026-2031)
 Table 29. Global New Molecular Entity (NME) Drug Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global New Molecular Entity (NME) Drug Revenue Market Share by Application (2020-2025)
 Table 31. Global New Molecular Entity (NME) Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global New Molecular Entity (NME) Drug Revenue Market Share by Application (2026-2031)
 Table 33. North America New Molecular Entity (NME) Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America New Molecular Entity (NME) Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America New Molecular Entity (NME) Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe New Molecular Entity (NME) Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe New Molecular Entity (NME) Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe New Molecular Entity (NME) Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific New Molecular Entity (NME) Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific New Molecular Entity (NME) Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific New Molecular Entity (NME) Drug Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America New Molecular Entity (NME) Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America New Molecular Entity (NME) Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America New Molecular Entity (NME) Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa New Molecular Entity (NME) Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa New Molecular Entity (NME) Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa New Molecular Entity (NME) Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 48. UCB Company Details
 Table 49. UCB Business Overview
 Table 50. UCB New Molecular Entity (NME) Drug Product
 Table 51. UCB Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 52. UCB Recent Development
 Table 53. Otsuka Pharmaceutical Company Details
 Table 54. Otsuka Pharmaceutical Business Overview
 Table 55. Otsuka Pharmaceutical New Molecular Entity (NME) Drug Product
 Table 56. Otsuka Pharmaceutical Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 57. Otsuka Pharmaceutical Recent Development
 Table 58. Eli Lilly Company Details
 Table 59. Eli Lilly Business Overview
 Table 60. Eli Lilly New Molecular Entity (NME) Drug Product
 Table 61. Eli Lilly Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 62. Eli Lilly Recent Development
 Table 63. Genentech Company Details
 Table 64. Genentech Business Overview
 Table 65. Genentech New Molecular Entity (NME) Drug Product
 Table 66. Genentech Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 67. Genentech Recent Development
 Table 68. Eisai Company Details
 Table 69. Eisai Business Overview
 Table 70. Eisai New Molecular Entity (NME) Drug Product
 Table 71. Eisai Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 72. Eisai Recent Development
 Table 73. Biogen Company Details
 Table 74. Biogen Business Overview
 Table 75. Biogen New Molecular Entity (NME) Drug Product
 Table 76. Biogen Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 77. Biogen Recent Development
 Table 78. Menarini Group Company Details
 Table 79. Menarini Group Business Overview
 Table 80. Menarini Group New Molecular Entity (NME) Drug Product
 Table 81. Menarini Group Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 82. Menarini Group Recent Development
 Table 83. GSK Company Details
 Table 84. GSK Business Overview
 Table 85. GSK New Molecular Entity (NME) Drug Product
 Table 86. GSK Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 87. GSK Recent Development
 Table 88. Chest Company Details
 Table 89. Chest Business Overview
 Table 90. Chest New Molecular Entity (NME) Drug Product
 Table 91. Chest Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 92. Chest Recent Development
 Table 93. Travere Company Details
 Table 94. Travere Business Overview
 Table 95. Travere New Molecular Entity (NME) Drug Product
 Table 96. Travere Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 97. Travere Recent Development
 Table 98. Reata Company Details
 Table 99. Reata Business Overview
 Table 100. Reata New Molecular Entity (NME) Drug Product
 Table 101. Reata Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 102. Reata Recent Development
 Table 103. Pfizer Company Details
 Table 104. Pfizer Business Overview
 Table 105. Pfizer New Molecular Entity (NME) Drug Product
 Table 106. Pfizer Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 107. Pfizer Recent Development
 Table 108. Acadia Pharmaceuticals Company Details
 Table 109. Acadia Pharmaceuticals Business Overview
 Table 110. Acadia Pharmaceuticals New Molecular Entity (NME) Drug Product
 Table 111. Acadia Pharmaceuticals Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 112. Acadia Pharmaceuticals Recent Development
 Table 113. Incyte Company Details
 Table 114. Incyte Business Overview
 Table 115. Incyte New Molecular Entity (NME) Drug Product
 Table 116. Incyte Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 117. Incyte Recent Development
 Table 118. Cidara Company Details
 Table 119. Cidara Business Overview
 Table 120. Cidara New Molecular Entity (NME) Drug Product
 Table 121. Cidara Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 122. Cidara Recent Development
 Table 123. Melinta Company Details
 Table 124. Melinta Business Overview
 Table 125. Melinta New Molecular Entity (NME) Drug Product
 Table 126. Melinta Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 127. Melinta Recent Development
 Table 128. Pharming Company Details
 Table 129. Pharming Business Overview
 Table 130. Pharming New Molecular Entity (NME) Drug Product
 Table 131. Pharming Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 132. Pharming Recent Development
 Table 133. LEO Pharma Company Details
 Table 134. LEO Pharma Business Overview
 Table 135. LEO Pharma New Molecular Entity (NME) Drug Product
 Table 136. LEO Pharma Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 137. LEO Pharma Recent Development
 Table 138. Novartis Company Details
 Table 139. Novartis Business Overview
 Table 140. Novartis New Molecular Entity (NME) Drug Product
 Table 141. Novartis Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 142. Novartis Recent Development
 Table 143. Argenx Company Details
 Table 144. Argenx Business Overview
 Table 145. Argenx New Molecular Entity (NME) Drug Product
 Table 146. Argenx Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 147. Argenx Recent Development
 Table 148. Takeda Company Details
 Table 149. Takeda Business Overview
 Table 150. Takeda New Molecular Entity (NME) Drug Product
 Table 151. Takeda Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 152. Takeda Recent Development
 Table 153. AbbVie Company Details
 Table 154. AbbVie Business Overview
 Table 155. AbbVie New Molecular Entity (NME) Drug Product
 Table 156. AbbVie Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 157. AbbVie Recent Development
 Table 158. Bayer Hlthcare Company Details
 Table 159. Bayer Hlthcare Business Overview
 Table 160. Bayer Hlthcare New Molecular Entity (NME) Drug Product
 Table 161. Bayer Hlthcare Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 162. Bayer Hlthcare Recent Development
 Table 163. Sanofi Company Details
 Table 164. Sanofi Business Overview
 Table 165. Sanofi New Molecular Entity (NME) Drug Product
 Table 166. Sanofi Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 167. Sanofi Recent Development
 Table 168. Immumnocore Company Details
 Table 169. Immumnocore Business Overview
 Table 170. Immumnocore New Molecular Entity (NME) Drug Product
 Table 171. Immumnocore Revenue in New Molecular Entity (NME) Drug Business (2020-2025) & (US$ Million)
 Table 172. Immumnocore Recent Development
 Table 173. Research Programs/Design for This Report
 Table 174. Key Data Information from Secondary Sources
 Table 175. Key Data Information from Primary Sources
 Table 176. Authors List of This Report


List of Figures
 Figure 1. New Molecular Entity (NME) Drug Picture
 Figure 2. Global New Molecular Entity (NME) Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global New Molecular Entity (NME) Drug Market Share by Type: 2024 VS 2031
 Figure 4. Antibody Features
 Figure 5. Polypeptide Features
 Figure 6. Small Molecule Drug Features
 Figure 7. Other Features
 Figure 8. Global New Molecular Entity (NME) Drug Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global New Molecular Entity (NME) Drug Market Share by Application: 2024 VS 2031
 Figure 10. Hospital Case Studies
 Figure 11. Clinic Case Studies
 Figure 12. New Molecular Entity (NME) Drug Report Years Considered
 Figure 13. Global New Molecular Entity (NME) Drug Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global New Molecular Entity (NME) Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global New Molecular Entity (NME) Drug Market Share by Region: 2024 VS 2031
 Figure 16. Global New Molecular Entity (NME) Drug Market Share by Players in 2024
 Figure 17. Global Top New Molecular Entity (NME) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in New Molecular Entity (NME) Drug as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by New Molecular Entity (NME) Drug Revenue in 2024
 Figure 19. North America New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America New Molecular Entity (NME) Drug Market Share by Country (2020-2031)
 Figure 21. United States New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe New Molecular Entity (NME) Drug Market Share by Country (2020-2031)
 Figure 25. Germany New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific New Molecular Entity (NME) Drug Market Share by Region (2020-2031)
 Figure 33. China New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America New Molecular Entity (NME) Drug Market Share by Country (2020-2031)
 Figure 41. Mexico New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa New Molecular Entity (NME) Drug Market Share by Country (2020-2031)
 Figure 45. Turkey New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE New Molecular Entity (NME) Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UCB Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 49. Otsuka Pharmaceutical Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 50. Eli Lilly Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 51. Genentech Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 52. Eisai Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 53. Biogen Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 54. Menarini Group Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 55. GSK Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 56. Chest Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 57. Travere Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 58. Reata Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 59. Pfizer Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 60. Acadia Pharmaceuticals Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 61. Incyte Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 62. Cidara Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 63. Melinta Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 64. Pharming Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 65. LEO Pharma Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 66. Novartis Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 67. Argenx Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 68. Takeda Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 69. AbbVie Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 70. Bayer Hlthcare Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 71. Sanofi Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 72. Immumnocore Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2020-2025)
 Figure 73. Bottom-up and Top-down Approaches for This Report
 Figure 74. Data Triangulation
 Figure 75. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6Q20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35Z19949
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26E19785
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions